Global Critical Limb Ischemia Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

Global Critical Limb Ischemia Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

  • August 2019 •
  • 112 pages •
  • Report ID: 5811436 •
  • Format: PDF
High levels of pipeline activity are being observed in Critical Limb Ischemia treatment during 2019. Clinical development activities are being undertaken by more than 25 companies including Anaeropharma Science, Inc., AnGes MG Inc, Antidote Therapeutics Inc, Apceth Biopharma GmbH, Athersys, Inc. and others.

A Significant contribution to the Critical Limb Ischemia pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Critical Limb Ischemia pipeline included 29 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Critical Limb Ischemia condition and increased access to investments is encouraging growth of Critical Limb Ischemia drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Critical Limb Ischemia drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Critical Limb Ischemia therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Critical Limb Ischemia pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Critical Limb Ischemia. Further, orphan drug status, fast track designation, grants awarded and other special status for Critical Limb Ischemia pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Critical Limb Ischemia pipeline and formulate effective research and development strategies.

Research Methodology
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Critical Limb Ischemia Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Critical Limb Ischemia drugs
- Late phase: Phase 3 and in-approval Critical Limb Ischemia drugs

Companies involved in the Pipeline-
- Company overview
- Snapshot
- Critical Limb Ischemia therapeutic treatment activities

Details for each Critical Limb Ischemia drug candidate-
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details

Other details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate

Recent Critical Limb Ischemia therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news